Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 8/20 | 0.47 |
| ▸ | PTGES | O14684 | 3/20 | 0.46 |
| ▸ | KDR | P35968 | 1/20 | 0.44 |
| ▸ | APOB | P04114 | 4/20 | 0.44 |
| ▸ | MTTP | P55157 | 4/20 | 0.44 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.41 |
| ▸ | SMO | Q99835 | 2/20 | 0.40 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19973650 | 0.90 | TRPV1 (0.48) | TRPV1PTGESGRM4PTGS1 | |
| SCHEMBL19973651 | 0.90 | TRPV1 (0.48) | TRPV1PTGESGRM4PTGS1 | |
| SCHEMBL21189262 | 0.90 | TP53 (0.42) | TRPV1PTGESAPOBMTTP | |
| SCHEMBL21189485 | 0.90 | TP53 (0.42) | TRPV1PTGESAPOBMTTP | |
| SCHEMBL21189206 | 0.90 | TP53 (0.42) | TRPV1PTGESAPOBMTTP | |
| SCHEMBL21189284 | 0.88 | APOB (0.42) | TRPV1PTGESAPOBMTTPSMO | |
| SCHEMBL21189278 | 0.87 | FADS1 (0.46) | PTGESAPOBMTTP | |
| SCHEMBL19973620 | 0.86 | RXFP1 (0.51) | PTGS1 | |
| SCHEMBL21189267 | 0.85 | AKR1C3 (0.38) | TRPV1PTGESAPOBMTTP | |
| SCHEMBL21189281 | 0.85 | LMNA (0.41) | TRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11001564-B2 | Substituted chromane-8-carboxamide compounds and analogues thereof, and methods using same | ARBUTUS BIOPHARMA CORPORATION (CA) | 2021-05-11 | — | — | US | disclosed |
| US-20190225593-A1 | SUBSTITUTED CHROMANE-8-CARBOXAMIDE COMPOUNDS AND ANALOGUES THEREOF, AND METHODS USING SAME | ARBUTUS BIOPHARMA CORP (CA) | 2019-07-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190225593-A1 | SUBSTITUTED CHROMANE-8-CARBOXAMIDE COMPOUNDS AND ANALOGUES THEREOF, AND METHODS USING SAME | CBX8, HAVCR2, HCCS | TRPV1 3647/4885PTGES 4518/4885KDR 4106/4885 |
| US-11001564-B2 | Substituted chromane-8-carboxamide compounds and analogues thereof, and methods using same | CBX8, HAVCR2, HCCS | TRPV1 3647/4885PTGES 4518/4885KDR 4106/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.